Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15645
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2014English

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma

Case Reports in Hematology
2016English

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Hematology
Hematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy